The Microbiome Therapeutics Innovation Group names Dr Ken Blount as new chairman
2 July 2019 -

The Microbiome Therapeutics Innovation Group (MTIG), a coalition of companies that research and develop FDA-approved microbiome therapeutics and microbiome-based products, revealed on Tuesday that Ken Blount PhD, chief scientific officer of Rebiotix Inc, has been appointed to the role of chairman.

MTIG stated that Dr Blount replaces Tom DesRosier Esq, chief legal officer of Seres Therapeutics, who served as MTIG Chairman since the inception of the coalition in 2018. DesRosier will continue to serve on the MTIG board of directors.

Pharmaceutical and biotechnology companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products are eligible for consideration of membership in MTIG, which is comprised of three microbiome therapeutics companies: Rebiotix, Inc, Seres Therapeutics and Vedanta Biosciences.

According to MTIG, the human microbiome is a new frontier of medical innovation that may benefit patients suffering from numerous diseases. The MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and enable the field to fulfil its potential.